Chen J, Shen T, Li J, Ling S, Yang Z, Wang G, Sun L, Yang Z, Zhuang L, Gao J et al (2022) Clinical practice guideline on liver transplantation for hepatocellular carcinoma in China (2021 edition). CMJ 2911–2913

Chew SC, Choo SY, Chow PK (2021) A new perspective on the immune escape mechanism in HCC: onco-foetal reprogramming. Br J Cancer 124:1897–1899

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giovannini C, Gramantieri L, Chieco P, Minguzzi M, Lago F, Pianetti S, Ramazzotti E, Marcu KB, Bolondi L (2009) Selective ablation of Notch3 in HCC enhances doxorubicin’s death promoting effect by a p53 dependent mechanism. J Hepatol 50:969–979

Article  CAS  PubMed  Google Scholar 

Gu J-H, Zhao Q-Y, He C, Ye Z-D, Xu M, Jiang T-A (2021) Fusion imaging-guided radiofrequency ablation for residual hepatocellular carcinoma invisible on ultrasound after transcatheter arterial chemoembolization. Int J Hyperth 38:1092–1098

Article  CAS  Google Scholar 

Gu J, Xu S, Chen X, Luo H, Tan G, Qi W, Ling F, Wang C, Maimaiti F, Chen Y et al (2022) ORM 1 as a biomarker of increased vascular invasion and decreased sorafenib sensitivity in hepatocellular carcinoma. Bosn J Basic Med Sci 22:949–958

Article  CAS  PubMed  PubMed Central  Google Scholar 

He L, Yuan L, Yu W, Sun Y, Jiang D, Wang X, Feng X, Wang Z, Xu J, Yang R et al (2020) A Regulation Loop between YAP and NR4A1 balances cell proliferation and apoptosis. Cell Rep 33:108284

Article  CAS  PubMed  Google Scholar 

Hu ZG, Chen YB, Huang M, Tu JB, Tu SJ, Pan YJ, Chen XL, He SQ (2021) PLG inhibits Hippo signaling pathway through SRC in the hepatitis B virus-induced hepatocellular-carcinoma progression. Am J Transl Res 13:515–531

CAS  PubMed  PubMed Central  Google Scholar 

Huang A, Yang XR, Chung WY, Dennison AR, Zhou J (2020) Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther 5:146

Article  PubMed  PubMed Central  Google Scholar 

Kong FH, Ye QF, Miao XY, Liu X, Huang SQ, Xiong L, Wen Y, Zhang ZJ (2021) Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma. Theranostics 11:5464–5490

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K et al (2020) Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 69:1492–1501

Article  PubMed  Google Scholar 

Liu Y, Zhang Q, Xing B, Luo N, Gao R, Yu K, Hu X, Bu Z, Peng J, Ren X et al (2022) Immune phenotypic linkage between colorectal cancer and liver metastasis. Cancer Cell 40:424–437 e425

Article  PubMed  Google Scholar 

Liu Y, Xun Z, Ma K, Liang S, Li X, Zhou S, Sun L, Liu Y, Du Y, Guo X et al (2023) Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J Hepatol 78:770–782

Article  CAS  PubMed  Google Scholar 

Llovet JM, Montal R, Sia D, Finn RS (2018) Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol 15:599–616

Article  PubMed  Google Scholar 

McGlynn KA, Petrick JL, El-Serag HB (2021) Epidemiology of Hepatocellular Carcinoma. Hepatology 73(Suppl 1):4–13

Article  CAS  PubMed  Google Scholar 

Merritt CR, Ong GT, Church SE, Barker K, Danaher P, Geiss G, Hoang M, Jung J, Liang Y, McKay-Fleisch J et al (2020) Multiplex digital spatial profiling of proteins and RNA in fixed tissue. Nat Biotechnol 38:586–599

Article  CAS  PubMed  Google Scholar 

Meylan M, Petitprez F, Becht E, Bougouin A, Pupier G, Calvez A, Giglioli I, Verkarre V, Lacroix G, Verneau J et al (2022) Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity 55:527–541 e525

Article  CAS  PubMed  Google Scholar 

Mossmann D, Muller C, Park S, Ryback B, Colombi M, Ritter N, Weissenberger D, Dazert E, Coto-Llerena M, Nuciforo S et al (2023) Arginine reprograms metabolism in liver cancer via RBM39. Cell 186:5068–5083 e5023

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pan Q, Qin F, Yuan H, He B, Yang N, Zhang Y, Ren H, Zeng Y (2021) Normal tissue adjacent to tumor expression profile analysis developed and validated a prognostic model based on Hippo-related genes in hepatocellular carcinoma. Cancer Med 10:3139–3152

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau GY, Mazzaferro V, Roayaie S, Lee HC, Kokudo N et al (2019) Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut 68:1065–1075

Article  PubMed  Google Scholar 

Qin S, Bi F, Gu S, Bai Y, Chen Z, Wang Z, Ying J, Lu Y, Meng Z, Pan H et al (2021) Donafenib Versus Sorafenib in First-Line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, Open-Label, parallel-controlled phase II-III trial. J Clin Oncol 39:3002–3011

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roelands J, van der Ploeg M, Ijsselsteijn ME, Dang H, Boonstra JJ, Hardwick JCH, Hawinkels L, Morreau H, de Miranda N (2023) Transcriptomic and immunophenotypic profiling reveals molecular and immunological hallmarks of colorectal cancer tumourigenesis. Gut 72:1326–1339

Article  CAS  PubMed  Google Scholar 

Sangro B, Sarobe P, Hervas-Stubbs S, Melero I (2021) Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 18:525–543

Article  PubMed  PubMed Central  Google Scholar 

Sathe A, Mason K, Grimes SM, Zhou Z, Lau BT, Bai X, Su A, Tan X, Lee H, Suarez CJ et al (2023) Colorectal Cancer metastases in the liver establish immunosuppressive spatial networking between Tumor-Associated SPP1 + macrophages and fibroblasts. Clin Cancer Res 29:244–260

Article  CAS  PubMed  Google Scholar 

Schmitd LB, Perez-Pacheco C, Bellile EL, Wu W, Casper K, Mierzwa M, Rozek LS, Wolf GT, Taylor JMG, D’Silva NJ (2022) Spatial and transcriptomic analysis of Perineural Invasion in oral Cancer. Clin Cancer Res 28:3557–3572

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun Y, Wu L, Zhong Y, Zhou K, Hou Y, Wang Z, Zhang Z, Xie J, Wang C, Chen D et al (2021) Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell 184:404–421 e416

Article  CAS  PubMed  Google Scholar 

Tan Y, Li Y (2015) HCV core protein promotes hepatocyte proliferation and chemoresistance by inhibiting NR4A1. Biochem Biophys Res Commun 466:592–598

Article  CAS  PubMed  Google Scholar 

Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, Wang Q, Wang S, Rong D, Reiter FP et al (2020) The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther 5:87

Article  PubMed  PubMed Central  Google Scholar 

Wu R, Guo W, Qiu X, Wang S, Sui C, Lian Q, Wu J, Shan Y, Yang Z, Yang S et al (2021) Comprehensive analysis of spatial architecture in primary liver cancer. Sci Adv 7:eabg3750

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xia S, Pan Y, Liang Y, Xu J, Cai X (2020) The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma. EBioMedicine 51

Xiong Z, Chan SL, Zhou J, Vong JSL, Kwong TT, Zeng X, Wu H, Cao J, Tu Y, Feng Y et al (2023) Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma. Gut 72:1758–1773

Article  CAS  PubMed  Google Scholar 

Zhang X, Liu X, Zhu K, Zhang X, Li N, Sun T, Fan S, Dai L, Zhang J (2022) CD5L-associated gene analyses highlight the dysregulations, prognostic effects, immune associations, and drug-sensitivity predicative potentials of LCAT and CDC20 in hepatocellular carcinoma. Cancer Cell Int 22:393